OncoGenex announces initiation of Phase 2 OGX-427 study with Zytiga OncoGenex Pharmaceuticals announced the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer who are experiencing a rising PSA while receiving Zytiga. The aim of the study is to determine if adding OGX-427 to Zytiga treatment can reverse or delay treatment resistance. The primary objective will be to compare the two treatment groups for delaying further disease progression while on Zytiga by assessing the progression-free survival rate at 60 days after adding OGX-427. Secondary objectives include comparing the treatment arms for PSA responses, objective responses, time to progression, circulating tumor cells and other biomarkers.
News For OGXI From The Last 14 Days
Check below for free stories on OGXI the last two weeks.